Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug HZN-825 tested for rare scleroderma lung and skin damage

NCT ID NCT04781543

Terminated Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tested an experimental drug called HZN-825 in about 300 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and can damage the lungs. Participants took either a low dose, a high dose, or a placebo daily for 52 weeks. The study aimed to see if HZN-825 could improve lung function and skin hardness, but it was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HZN-825
What this could lead to
If successful, HZN-825 could offer a new treatment option to slow lung and skin damage in people with diffuse cutaneous systemic sclerosis.
What could go wrong
This trial was terminated early, so results are limited. It was a phase 2 study, meaning it is still early-stage and may not lead to an approved treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse cutaneous systemic sclerosis diffuse scleroderma systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SCLEROSIS, SYSTEMIC

Contacts and locations

Locations

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, 08025, Spain

  • Institute for Treatment and Rehabilitation Niska Banja

    Niška Banja, 708120, Serbia

  • Institute of Rheumatology - PPDS

    Belgrade, 11000, Serbia

  • Military Medical Academy

    Belgrade, 11000, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.